Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
McKinsey
Merck
Baxter

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,757,406

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,757,406 protect, and when does it expire?

Patent 9,757,406 protects EPCLUSA and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 9,757,406
Title:Combination formulation of two antiviral compounds
Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: ##STR00001## and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
Inventor(s): Gorman; Eric (Foster City, CA), Mogalian; Erik (Foster City, CA), Oliyai; Reza (Foster City, CA), Stefanidis; Dimitrios (Mountain View, CA), Wiser; Lauren (San Francisco, CA), Zia; Vahid (Palo Alto, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:15/282,128
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Drugs Protected by US Patent 9,757,406

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc EPCLUSA sofosbuvir; velpatasvir TABLET;ORAL 208341-001 Jun 28, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,757,406

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 095133   Start Trial
Australia 2014311827   Start Trial
Australia 2017276223   Start Trial
Australia 2019264624   Start Trial
Canada 2921160   Start Trial
China 105517540   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Moodys
Harvard Business School
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.